Multimodal OCS approaches WTPthreshold in UK

Multimodal OCS approaches WTPthreshold in UK PharmacoEconomics & Outcomes News 784, p24 - 12 Aug 2017 Multimodal OCS approaches WTP threshold in UK Multimodal ovarian cancer screening (OCS) in the UK appears to approach NICE willingness-to-pay (WTP) thresholds, according to findings of a study published in the British Journal of Cancer. Investigators conducted a within-trial evaluation of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) to assess the cost-effectiveness of annual transvaginal ultrasound (TSS), or annual multimodal screening (MMS) including serum CA125 levels with risk of ovarian cancer algorithm (ROCA) interpretation and second-line TSS, compared with no screening in 202 638 women 50–75 years of age, from a National Health Service (NHS) perspective over a 14-year follow- up period. A predictive model was also used to evaluate the cost effectiveness of the MMS programme compared with no screening in the UKCTOCS population over a lifetime (25-year) time horizon, and a Markov model populated with UKCTOCS data used to evaluate the cost effectiveness of MMS compared with no screening in a hypothetical cohort over a lifetime time horizon. At an assumed cost of £20 for CA125-ROCA, within- trial analysis found that MMS dominated USS (more effective and less costly). The estimated incremental cost-effectiveness ratio (ICER) for MMS compared with ** no screening was £91 452 per life-year gained (LYG). The ICER was decreased to £77 818 per LYG if the cost of CA125-ROCA was reduced to £15. Predictive analysis of UKCTOCS data extrapolated over a lifetime resulted in an estimated ICER for MMS versus TSS of £30 033 per LYG, and Markov modelling resulted an ICER of £46 922 per QALY gained. "The findings are not only highly dependent on the average effect size of the mortality reduction associated with screening but also the cost of the CA125–ROCA test, assuming this test is adopted by the NHS," said the investigators. "Whether MMS could be recommended on economic grounds would depend on the confirmation and size of the mortality benefit at the end of an ongoing follow-up of the UKCTOCS cohort," they said. * National Institute for Health and Care Excellence ** 2013/2014 British pounds Menon U, et al. The cost-effectiveness of screening for ovarian cancer: results from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). British Journal of Cancer : 25 Jul 2017. Available from: URL: http:// doi.org/10.1038/bjc.2017.222 1173-5503/17/0784-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 12 Aug 2017 No. 784 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png PharmacoEconomics & Outcomes News Springer Journals

Multimodal OCS approaches WTPthreshold in UK

Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/multimodal-ocs-approaches-wtpthreshold-in-uk-hU0ZKctdcU
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG
Subject
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
ISSN
1173-5503
eISSN
1179-2043
D.O.I.
10.1007/s40274-017-4235-x
Publisher site
See Article on Publisher Site

Abstract

PharmacoEconomics & Outcomes News 784, p24 - 12 Aug 2017 Multimodal OCS approaches WTP threshold in UK Multimodal ovarian cancer screening (OCS) in the UK appears to approach NICE willingness-to-pay (WTP) thresholds, according to findings of a study published in the British Journal of Cancer. Investigators conducted a within-trial evaluation of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) to assess the cost-effectiveness of annual transvaginal ultrasound (TSS), or annual multimodal screening (MMS) including serum CA125 levels with risk of ovarian cancer algorithm (ROCA) interpretation and second-line TSS, compared with no screening in 202 638 women 50–75 years of age, from a National Health Service (NHS) perspective over a 14-year follow- up period. A predictive model was also used to evaluate the cost effectiveness of the MMS programme compared with no screening in the UKCTOCS population over a lifetime (25-year) time horizon, and a Markov model populated with UKCTOCS data used to evaluate the cost effectiveness of MMS compared with no screening in a hypothetical cohort over a lifetime time horizon. At an assumed cost of £20 for CA125-ROCA, within- trial analysis found that MMS dominated USS (more effective and less costly). The estimated incremental cost-effectiveness ratio (ICER) for MMS compared with ** no screening was £91 452 per life-year gained (LYG). The ICER was decreased to £77 818 per LYG if the cost of CA125-ROCA was reduced to £15. Predictive analysis of UKCTOCS data extrapolated over a lifetime resulted in an estimated ICER for MMS versus TSS of £30 033 per LYG, and Markov modelling resulted an ICER of £46 922 per QALY gained. "The findings are not only highly dependent on the average effect size of the mortality reduction associated with screening but also the cost of the CA125–ROCA test, assuming this test is adopted by the NHS," said the investigators. "Whether MMS could be recommended on economic grounds would depend on the confirmation and size of the mortality benefit at the end of an ongoing follow-up of the UKCTOCS cohort," they said. * National Institute for Health and Care Excellence ** 2013/2014 British pounds Menon U, et al. The cost-effectiveness of screening for ovarian cancer: results from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). British Journal of Cancer : 25 Jul 2017. Available from: URL: http:// doi.org/10.1038/bjc.2017.222 1173-5503/17/0784-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 12 Aug 2017 No. 784

Journal

PharmacoEconomics & Outcomes NewsSpringer Journals

Published: Aug 12, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off